Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol ED90 with oliceridine versus fentanyl for upper gastrointestinal endoscopy insertion response
ChiCTR2500096971Phase 4Not yet recruiting
- Sponsor
- Changshu No.2 People's Hospital
- Start
- Feb 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of propofol, oliceridine and fentanyl (2 arms), sponsored by Changshu No.2 People's Hospital. Primary endpoint: 90% effective dose for inhibiting the insertion response in upper gastrointestinal endoscopy. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
propofololiceridinefentanyl
Beyond the preview
Go deeper on ChiCTR2500096971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096971.